Articles related to MYELOMA

Teclistamab, a BCMA bispecific antibody, demonstrates a promising 63% overall response rate in heavily pretreated R/R MM patients, with manageable toxicity compared to CAR T-cell therapy.

Secondary malignancies like indolent CD4+ CAR T-cell lymphoma can emerge after CAR T-cell therapy. This case highlights the importance of recognizing and thoroughly investigating these rare complications.

A recent phase 3 trial demonstrates that a combination therapy of belantamab mafodotin, bortezomib, and dexamethasone leads to significantly longer progression-free survival in patients with relapsed or refractory multiple myeloma compared to a regimen including daratumumab.

High-risk iFISH markers, such as CKS1B, IGH-FGFR3, and del17p, significantly affect survival outcomes in newly diagnosed multiple myeloma patients, with marked differences observed between high-risk and standard-risk cohorts.

This study introduces a pivotal model that aids physicians in making informed decisions regarding bone marrow sampling for MGUS patients, utilizing a comprehensive set of biomarkers to predict the progression to SMM or worse conditions with high accuracy.

Explore the recent FDA approval of biweekly teclistamab dosing for multiple myeloma, a significant stride in offering personalized treatment schedules that cater to patient and clinician needs.